Adjuvant Pembrolizumab Cuts Recurrence in Stage II Melanoma

Compared with placebo, pembrolizumab prolonged regression - free survival in resected high - risk stage IIB and IIC melanoma
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news